Neurological complications in the primary antiphospholipid syndrome include stroke, multi-infarct dementia, migraine, chorea, epilepsy and transverse myelitisl. We present a case of sudden ageusia (loss of taste) in which antiphospholipid antibodies were thought relevant to pathogenesis.
CASE HISTORY
A woman aged 72 suddenly lost her ability to taste. There was no associated anosmia, dysphagia, facial weakness or headache. She was taking bendrofluazide for hypertension and propranolol for migraine. She had never had a miscarriage, but there was a strong family history of stroke. There were no symptoms suggestive of a connective tissue disorder.
Examination confirmed total ageusia to all modalities of taste without other neurological abnormality; she was normotensive. Haemoglobin was 12 g/dL, platelet count 275 x 109/L, erythrocyte-sedimentation rate 49mm/h. Her partial thromboplastin time was prolonged (50 seconds, control 38) and its non-correction by addition of an equal volume of normal plasma suggested the presence of an inhibitor of coagulation. Protein C and S concentrations and antithrombin III activity were normal. Anticardiolipin IgG antibody was present in a titre of > 100 GPLU/mL (normal 0-15). Resistance to activated protein C was not demonstrated. She had a positive antinuclear antibody with a titre of 1:320 (fine speckled pattern) but a negative screen for extractable nuclear antigens and antineutrophil cytoplasmic antibodies. Temporal artery biopsy and echocardiogram were normal. Magnetic resonance imaging of the brain and brainstem (T2-weighted) revealed multiple small high-signal areas in the thalami, subcortical white matter, periventricular area, pons and upper medulla bilaterally ( Figure 1 ). The ageusia was attributed to bilateral vascular lesions of the nucleus of tractus solitarius (gustatory nucleus) in the brainstem, as a manifestation of the primary antiphospholipid syndrome. She was anticoagulated with warfarin. Eighteen months later she was regaining some ability to taste strong flavours and no new symptoms had developed. COMMENT Total ageusia is very rare as an isolated symptom. Previous case reports of ageusia due to central lesions have been related to tumours and demyelination2. This patient's lesions seen on magnetic resonance imaging are likely to be small infarcts affecting the tractus solitarius and possibly the thalamus.
The antiphospholipid syndrome was first described in patients with systemic lupus erythematosus (SLE) in whom widespread arterial and venous thrombosis was associated with thrombocytopenia and recurrent abortion3. Many other features have since been reported, with neurological involvement often dominating the clinical picture. Cerebral ischaemia is probably the most important-in the form of stroke, transient ischaemic attacks, amaurosis fugax and multi-infarct dementia. In this patient the diagnosis is suggested by the history of migraine, the positive lupus anticoagulant and the high titre of anticardiolipin IgG antibodies. The only other explanation would be infarction related to longstanding hypertension, but the clinical presentation and magnetic resonance changes are not typical of hypertensive cerebrovascular disease. The patient has a positive antinuclear antibody but no other criteria for diagnosis of SLE. The antiphospholipid syndrome has been reported to predate the development of SLE Treatment options include antiplatelet therapy, immunosuppression and anticoagulation. Aspirin, which lowers the rate of fetal loss in the syndrome (in conjunction with low-dose subcutaneous heparin), may have a place for primary prophylaxis in those with high titres of antiphospholipid antibodies. Immunosuppression can lower titres of anticardiolipin antibodies but does not always prevent recurrence of thrombosis5 or improve other aspects of the syndrome. In patients with a proven thrombotic event lifelong anticoagulation is currently the most satisfactory therapeutic strategy. The hazards of anticoagulation in a patient with longstanding controlled hypertension are difficult to quantify, but in this case we felt that they were outweighed by the risk of further vasculopathy. , 26 FEBRUARY 1998 In most industrialized countries prostatic adenocarcinoma is the second most common cause of cancer death in men. We report a case that highlights the value of prostatic immunoscintigraphy in management.
A man aged 62 had urinary retention following haemorrhoidectomy. There were no previous symptoms of bladder outflow obstruction and he was in good general health. On digital rectal examination the prostate gland was smooth and symmetrically enlarged. Serum prostate specific antigen (PSA) was raised at 7.7/,g/L (normal <4,ug/L). A transrectal ultrasound scan showed a well-defined hypoechoic area with increased colour flow in the right anterior gland. Four ultrasound-guided systematic biopsies were taken, with 18 gauge needle and automatic biopsy gun, from the lesion, from the right and left lobes and from the apex and a well-differentiated adenocarcinoma (Figure 1 ) was identified at the site of the ultrasonographic abnormality. The other biopsies were clear, and a scintigraphic bone scan showed no metastatic lesions.
Presented with the therapeutic options, the patient elected to undergo radical prostatectomy. This was done, with pelvic lymphadenectomy, 17 weeks later. Whole mount sections of the prostate (Figure 2 ) at 5 mm intervals 
